NASDAQ:PRAH - PRA Health Sciences Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $145.00
  • Forecasted Upside: -13.40 %
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 8 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.07 (-0.04%)

This chart shows the closing price for PRAH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PRA Health Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRAH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRAH

Analyst Price Target is $145.00
▼ -13.40% Downside Potential
This price target is based on 10 analysts offering 12 month price targets for PRA Health Sciences in the last 3 months. The average price target is $145.00, with a high forecast of $175.00 and a low forecast of $100.00. The average price target represents a -13.40% upside from the last price of $167.43.

This chart shows the closing price for PRAH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 10 contributing investment analysts is to hold stock in PRA Health Sciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 8 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021Truist SecuritiesReiterated RatingBuy ➝ Hold$196.00 ➝ $175.00Low
5/10/2021Truist SecuritiesDowngradeBuy ➝ Hold$196.00 ➝ $175.00Medium
5/10/2021TruistDowngradeBuy ➝ Hold$196.00 ➝ $175.00Medium
4/29/2021Credit Suisse GroupBoost Price TargetOutperform$159.00 ➝ $169.00Low
4/26/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$165.00N/A
4/20/2021Robert W. BairdDowngradeOutperform ➝ Neutral$165.00Low
3/19/2021MizuhoBoost Price Target$110.00 ➝ $155.00Low
3/15/2021KeyCorpReiterated RatingOverweight ➝ Sector WeightLow
2/25/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
1/21/2021Robert W. BairdBoost Price TargetOutperform$130.00 ➝ $145.00Low
11/5/2020Credit Suisse GroupBoost Price TargetOutperform$120.00 ➝ $125.00High
8/10/2020UBS GroupBoost Price TargetNeutral$105.00 ➝ $111.00Medium
8/10/2020Bank of AmericaDowngradeBuy ➝ Underperform$110.00 ➝ $100.00Low
8/10/2020MizuhoBoost Price TargetNeutral ➝ In-Line$92.00 ➝ $108.00Low
8/10/2020CitigroupBoost Price TargetNeutral$90.00 ➝ $110.00Low
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$113.00 ➝ $116.00Medium
5/5/2020UBS GroupLower Price TargetNeutral$103.00 ➝ $101.00Low
5/4/2020SunTrust BanksBoost Price TargetBuy$89.00 ➝ $103.00Low
5/4/2020Robert W. BairdLower Price TargetOutperform$106.00 ➝ $101.00Medium
5/1/2020Credit Suisse GroupLower Price TargetOutperform$122.00 ➝ $113.00High
5/1/2020William BlairDowngradeOutperform ➝ Market PerformHigh
4/28/2020UBS GroupLower Price TargetNeutral$116.00 ➝ $103.00Low
4/13/2020Wolfe ResearchDowngradeOutperform ➝ Market Perform$97.00Medium
4/9/2020CitigroupLower Price TargetNeutral$120.00 ➝ $90.00High
4/3/2020MizuhoLower Price TargetNeutral$95.00 ➝ $82.00High
3/26/2020BarclaysLower Price TargetOverweight$123.00 ➝ $114.00Medium
3/23/2020Jefferies Financial GroupLower Price TargetBuy$125.00 ➝ $89.00Low
3/17/2020SunTrust BanksLower Price TargetBuy$127.00 ➝ $89.00High
2/21/2020Robert W. BairdBoost Price TargetOutperform$122.00 ➝ $128.00High
1/10/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$130.00 ➝ $120.00High
1/6/2020CitigroupInitiated CoverageNeutral$120.00Medium
11/14/2019Wolfe ResearchUpgradePeer Perform ➝ Outperform$123.00Medium
9/19/2019The Goldman Sachs GroupInitiated CoverageBuy$126.00Low
9/6/2019Jefferies Financial GroupBoost Price TargetBuy$115.00 ➝ $120.00Low
9/4/2019BarclaysBoost Price TargetOverweight$115.00 ➝ $118.00High
7/2/2019SVB LeerinkReiterated RatingMarket PerformMedium
5/3/2019MizuhoSet Price TargetHold$100.00Low
4/2/2019Wolfe ResearchInitiated CoverageMarket PerformMedium
3/4/2019SunTrust BanksBoost Price TargetBuy ➝ Average$120.00Low
2/28/2019Robert W. BairdBoost Price TargetOutperform ➝ Outperform$119.00 ➝ $122.00High
11/5/2018SunTrust BanksBoost Price TargetBuy$120.00Medium
10/9/2018UBS GroupInitiated CoverageNeutral ➝ NeutralMedium
10/4/2018Evercore ISIInitiated CoverageIn-Line ➝ Inline$120.00High
9/11/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $116.00Low
8/6/2018MizuhoSet Price TargetHold$100.00High
8/3/2018SunTrust BanksBoost Price TargetAverage ➝ Buy$100.00 ➝ $110.00Low
8/2/2018KeyCorpReiterated RatingBuy$115.00Low
8/2/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$104.00 ➝ $107.00Low
8/2/2018BarclaysBoost Price TargetOverweight ➝ Overweight$100.00 ➝ $115.00Low
7/20/2018Jefferies Financial GroupReiterated RatingBuy$115.00Medium
2/22/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$101.00 ➝ $104.00High
1/31/2018KeyCorpReiterated RatingBuy$100.00Low
1/24/2018MizuhoDowngradeBuy ➝ Neutral$86.00High
12/15/2017Mitsubishi UFJ Financial GroupInitiated CoverageOverweight$102.00Low
12/11/2017BarclaysInitiated CoverageOverweight ➝ Overweight$94.00Medium
12/1/2017Robert W. BairdSet Price TargetBuy$94.00Low
12/1/2017MizuhoSet Price TargetBuy ➝ Buy$82.00 ➝ $87.00Low
10/30/2017KeyCorpReiterated RatingBuy$86.00 ➝ $93.00N/A
10/27/2017SunTrust BanksReiterated RatingBuy$101.00N/A
10/26/2017Credit Suisse GroupBoost Price TargetOutperform$90.00 ➝ $93.00N/A
10/26/2017Jefferies Financial GroupReiterated RatingBuy$95.00N/A
10/16/2017Credit Suisse GroupReiterated RatingOutperform$84.00 ➝ $90.00N/A
10/9/2017Robert W. BairdReiterated RatingBuy$88.00N/A
9/21/2017MizuhoInitiated CoverageBuy$82.00Low
8/16/2017Raymond JamesInitiated CoverageOutperform ➝ Outperform$89.00Low
8/10/2017Jefferies Financial GroupReiterated RatingBuy$88.00 ➝ $92.00Low
8/10/2017CitigroupReiterated RatingBuy$90.00 ➝ $93.00Low
8/9/2017SunTrust BanksReiterated RatingBuyHigh
8/8/2017Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$80.00 ➝ $84.00High
8/8/2017Robert W. BairdBoost Price TargetOutperform$82.00 ➝ $83.00High
6/28/2017CitigroupReiterated RatingBuy$73.00 ➝ $90.00Low
6/26/2017Bank of AmericaInitiated CoverageBuy$89.00Low
6/6/2017Credit Suisse GroupReiterated RatingOutperform$69.00 ➝ $76.00Low
6/1/2017Jefferies Financial GroupSet Price TargetBuy$73.00Low
4/28/2017Jefferies Financial GroupBoost Price TargetBuy$72.00 ➝ $72.50Low
2/27/2017Avondale PartnersUpgradeUnderperform ➝ Market Perform$63.00N/A
2/23/2017Jefferies Financial GroupReiterated RatingBuy$66.00N/A
2/6/2017Credit Suisse GroupUpgradeNeutral ➝ Outperform$67.00N/A
1/24/2017Jefferies Financial GroupBoost Price TargetBuy$63.00 ➝ $66.00N/A
1/14/2017Jefferies Financial GroupReiterated RatingBuy$63.00N/A
11/4/2016KeyCorpReiterated RatingBuyN/A
11/3/2016Credit Suisse GroupReiterated RatingHold$50.00N/A
9/22/2016CitigroupBoost Price TargetBuy$55.00 ➝ $66.00N/A
9/13/2016Jefferies Financial GroupReiterated RatingBuyN/A
9/6/2016UBS GroupDowngradeBuy ➝ Neutral$50.00 ➝ $55.00N/A
7/29/2016UBS GroupReiterated RatingBuy$50.00N/A
7/29/2016Jefferies Financial GroupReiterated RatingBuy$57.00N/A
(Data available from 6/23/2016 forward)
PRA Health Sciences logo
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. It operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that allow clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Read More

Today's Range

Now: $167.43
Low: $166.23
High: $167.51

50 Day Range

MA: $168.62
Low: $155.91
High: $174.52

52 Week Range

Now: $167.43
Low: $90.79
High: $175.95


1,273,526 shs

Average Volume

715,635 shs

Market Capitalization

$10.85 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of PRA Health Sciences?

The following Wall Street research analysts have issued stock ratings on PRA Health Sciences in the last year: Bank of America Co., Citigroup Inc., Credit Suisse Group AG, Jefferies Financial Group Inc., KeyCorp, Mizuho, Robert W. Baird, Truist, Truist Securities, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for PRAH.

What is the current price target for PRA Health Sciences?

8 Wall Street analysts have set twelve-month price targets for PRA Health Sciences in the last year. Their average twelve-month price target is $145.00, suggesting a possible downside of 13.4%. Truist has the highest price target set, predicting PRAH will reach $175.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $100.00 for PRA Health Sciences in the next year.
View the latest price targets for PRAH.

What is the current consensus analyst rating for PRA Health Sciences?

PRA Health Sciences currently has 1 sell rating, 8 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PRAH, but not buy more shares or sell existing shares.
View the latest ratings for PRAH.

What other companies compete with PRA Health Sciences?

How do I contact PRA Health Sciences' investor relations team?

PRA Health Sciences' physical mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company's listed phone number is (919) 786-8200 and its investor relations email address is [email protected] The official website for PRA Health Sciences is